Video

How Manufacturing Changes Can Create Risk For MSCs

Source: Cell & Gene

In this segment of Cell & Gene Live, Scaling Next-Gen MSC Therapies Without Scaling Risk, Miguel Forte, M.D., Ph.D., CEO and Co-Founder, Kiji Therapeutics, Michael Schuster, Director of Business Development, Mesoblast, and Edward Ahn, Ph.D., CEO and Director, MEDIPOST Inc. address the transition from early development into larger-scale manufacturing and why process changes can introduce biological and comparability risks.

Access The Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)